Wave Life Sciences: Update on 48-week Data from FORWARD-53 Study

An update on Wave’s Phase 2 FORWARD-53 trial of WVE-N531, Wave’s exon skipping investigational therapy for Duchenne being investigated for individuals who are amenable to exon 53 skipping. We will share the recently announced 48-week FORWARD-53 data.

April 7, 2025
8 AM Pacific | 11 AM Eastern
REGISTER HERE